FDA expanded pembrolizumab and enfortumab vedotin-ejfv for all surgery-eligible adults with muscle-invasive bladder cancer following positive trial data. The Food and Drug Administration (FDA) has ...
PADCEV (enfortumab vedotin-ejfv) can cause severe and fatal cutaneous adverse reactions including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which occurred predominantly ...
Long-term data show watch-and-wait is viable for rectal cancer, with most regrowths salvageable despite adverse baseline MRI features. Long-term data presented at the ESMO GI 2026 Congress provide new ...
A real-world study presented at ESMO GI shows fruquintinib is effective in mCRC, with the best outcomes in the third-line setting. Findings from a retrospective, real-world analysis presented at the ...
Oncology nurse Kerry Mann details the protocols and patient-centered strategies for bringing advanced precision medicine to local community clinics. The landscape of cancer care is shifting as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results